Loading
Bruker Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 09 Jun 2025.
Bruker Corp: what insiders have been doing
This page follows insider dealings at Bruker Corp as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Billerica. The group dates from 1960. Over the twelve months to 18 October 2026, 55 filings were filed, from 19 insiders.
No insider bought on the market over the period, while 3 insiders filed 8 sales totalling €1.1M. The amount is not disclosed for 1 filing. Munch Mark filed the largest sale, €331k, on 13 January 2026.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
With 55 filings in twelve months, the company is more active than the median of 22 filings across the 5,458 companies we follow on the same exchange. Over the whole record (from 2021), the tally stands at 5 purchases and 16 sales. The 10-K for the year ended 31 December 2025 shows 3.44 bn USD of revenue and -8.6 m USD of net income.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
195
Thresholds
n/a
Buy Volume
€4M
5 ops. · all time
Sell Volume
€35M
16 ops. · all time
Who traded when
BuySaleMark Munch6 sales
Frank H. Laukien3 buys
Ornell John A1 sale
Thomas Bures1 buy
Wolfgang Pusch1 sale
Analyst consensus: bullish or bearish?
Analysts rate Bruker Corp Buy (bullish), based on 12 analysts. Average price target: US$63.83.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,004 of 24,148 companies
28.6
score / 100
Value26
Quality31
FCF yld0.2%
Earn yld-0.3%
EV/EBITDA34.3x
ROE-3.0%
Gross mgn46%
Net mgn-0.7%
Debt/EBITDA6.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$54.80
Analyst consensus
12 analystsBuy
US$50.00Target US$63.83(+16%)US$80.00
Income statement
RevenueUS$3.4B
Gross profitUS$1.6B46% margin
EBITDAUS$302.6M9% margin
Net income-US$22.5M-2.0% margin
Valuation
PER (forward)22.8x
P/Book3.5x
Beta1.22
Balance sheet & cash
Market capUS$8.3B
Total debtUS$2B
Free Cash FlowUS$13.9M
Debt / Equity76%
Profitability & ownership
ROE-3.0%
ROA3.1%
% insiders27.0%
% institutions95.8%
Last declaration on 16 September 2026
Declarations195 total
2,000 shares@ US$22.191.2% of flowCommon StockSEC:0001544635-26-000025:0
2,000 shares@ US$52.873.0% of flowCommon StockSEC:0001544635-26-000025:1
2,000 shares@ US$52.870.0011% mcap23.4% of flowCommonSEC144:0001950047-26-009478
29,463 shares0Common StockSEC:0001133649-26-000005:0
15,794 shares0Common StockSEC:0001327294-26-000005:0
2,724 shares@ US$57.707.9% of flowCommon StockSEC:0001327294-26-000005:1
2,000 shares@ US$57.603.2% of flowCommon StockSEC:0001544635-26-000023:1
14,443 shares0Common StockSEC:0001544635-26-000023:2
2,984 shares@ US$57.704.8% of flowCommon StockSEC:0001544635-26-000023:3
3,303 shares0Common StockSEC:0001544726-26-000002:0
16,898 shares0Common StockSEC:0001569832-26-000002:0
4,035 shares0Common StockSEC:0001787029-26-000004:0
3,120 shares0Common StockSEC:0002143997-26-000007:0
3,473 shares@ US$56.90100.0% of flowCommon StockSEC:0002143997-26-000007:1
4,760 shares@ US$57.700.5% of flowCommon StockSEC:0001133649-26-000005:1
2,000 shares@ US$22.191.2% of flowCommon StockSEC:0001544635-26-000023:0
3,473 shares@ US$56.900.0021% mcap100.0% of flowCommonSEC144:0001950047-26-008203
2,000 shares@ US$57.600.0012% mcap25.5% of flowCommonSEC144:0001950047-26-008151
4,838 shares@ US$57.020.5% of flowCommon StockSEC:0001133649-26-000003:0
1,410 shares@ US$57.024.0% of flowCommon StockSEC:0001327294-26-000003:0
1,619 shares@ US$57.022.6% of flowCommon StockSEC:0001544635-26-000021:0
2,361 shares@ US$53.410.2% of flowCommon StockSEC:0001133649-26-000002:0
4,564 shares@ US$56.320.5% of flowCommon StockSEC:0001133649-26-000002:1
1,600 shares@ US$53.414.3% of flowCommon StockSEC:0001327294-26-000002:0
1,289 shares@ US$56.323.6% of flowCommon StockSEC:0001327294-26-000002:1
25 of 195 declarations
About Bruker Corp
Bruker Corp. (Nasdaq: BRKR) is a U.S.-listed, technology-intensive scientific instrumentation and diagnostics company headquartered in Billerica, Massachusetts, United States. For international investors, Bruker is best understood as a high-value analytical tools platform serving life-science research, clinical and molecular diagnostics, materials research, microscopy and nanoanalysis, and selected industrial applications. The company was founded in 1960 by Professor Günther Laukien in Karlsruhe, Germany, and its roots are strongly tied to advanced spectroscopy. Over time, Bruker broadened from a specialist scientific-instruments business into a diversified global franchise with multiple product families and end markets. Management emphasizes Bruker’s market leadership in high-value analytical technologies and its global installed base, supported by sustained R&D investment.
Bruker’s business model is built around complementary platforms rather than a single product line. Core areas include life-science research instruments, mass spectrometry, NMR, microscopy, nanoanalysis, molecular diagnostics, clinical microbiology, and materials/industrial analysis. The portfolio also extends into application-focused solutions for food, environmental, and industrial quality control, as well as next-generation semiconductor metrology. Key products and systems include high-performance mass spectrometers, proteomics and metabolomics workflows, molecular diagnostic systems, spatial biology tools, and advanced analytical platforms used in academic, biopharma, hospital, and industrial laboratories. This breadth gives Bruker exposure to several secular growth themes: precision medicine, multi-omics, lab automation, and higher-throughput quality assurance.
Read moreShow less
Competitively, Bruker operates in a global market where differentiation depends on instrument performance, application depth, reliability, software integration, and recurring consumable/service pull-through. Its strength lies in combining leading-edge science with strong customer relationships in research institutions and translational healthcare. Bruker is not a mass-market player; it competes in premium niches where technical performance and workflow relevance matter more than price alone. That positioning supports a reputation for innovation, but also implies exposure to funding cycles in academia and capital spending patterns in life sciences and industrial end markets.
Geographically, Bruker has a broad international footprint, with activity across North America, Europe, and Asia, and a customer base spanning universities, hospitals, reference labs, pharma and biotech companies, and industrial users. The company’s U.S. market listing on Nasdaq and its American headquarters make it particularly visible to U.S. investors, while its origins and manufacturing/application presence remain global.
Recent developments underscore an active innovation-and-acquisition strategy. In 2025 and 2026, Bruker launched multiple new systems in proteomics, metabolomics, microbiology, dairy analysis, spatial biology, and nanoparticle characterization. It also announced targeted acquisitions, including biocrates and an increased ownership stake in TOFWERK, aiming to strengthen its mass spectrometry and applied-market capabilities. Overall, Bruker combines secular growth exposure, a science-driven brand, and a diversified product portfolio that should appeal to investors seeking healthcare-adjacent technology with international reach.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
